ResearcherUniversity of VeronaActive in the last 2 years
Enza Scarlato
Matched on ORCID iD 0009-0009-3263-9830; OpenAlex author ID A5034504444. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2024: 2 papers · 2025: 1 paper · 2026: 4 papers
Papers 7
- Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities. Co-author DOI 10.1016/j.ctrv.2026.103123↗
- Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from … Co-author DOI 10.1016/j.esmoop.2026.106964↗
- EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages. Co-author DOI 10.1038/s41388-026-03774-0↗
- Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Co-author DOI 10.1038/s41698-026-01442-w↗
- Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.esmogo.2025.100179↗
- CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Co-author DOI 10.1038/s41698-024-00742-3↗
- Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-23-0104↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Davide Melisi · 7 shared papers, 2024–2026 · strength 1.91
- Paper Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging oppo… DOI 10.1016/j.ctrv.2026.103123↗
- Paper EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-as… DOI 10.1038/s41388-026-03774-0↗
- Paper Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and … DOI 10.1016/j.esmoop.2026.106964↗
- Simona Casalino · 6 shared papers, 2024–2026 · strength 1.41
- Paper EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-as… DOI 10.1038/s41388-026-03774-0↗
- Paper Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and … DOI 10.1016/j.esmoop.2026.106964↗
- Paper Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LI… DOI 10.1038/s41698-026-01442-w↗
- Silvia Pietrobono · 5 shared papers, 2024–2026 · strength 1.17
- Paper EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-as… DOI 10.1038/s41388-026-03774-0↗
- Paper Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and … DOI 10.1016/j.esmoop.2026.106964↗
- Paper Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LI… DOI 10.1038/s41698-026-01442-w↗
- Valeria Merz · 4 shared papers, 2024–2026 · strength 0.90
- Paper Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and … DOI 10.1016/j.esmoop.2026.106964↗
- Paper Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LI… DOI 10.1038/s41698-026-01442-w↗
- Paper CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macroph… DOI 10.1038/s41698-024-00742-3↗
- Giovanni Butturini · 2 shared papers, 2025–2026 · strength 0.51
- Paper Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and … DOI 10.1016/j.esmoop.2026.106964↗
- Paper Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal ade… DOI 10.1016/j.esmogo.2025.100179↗
- Nelson Dusetti · 1 shared paper, 2026 · strength 0.50
- Roberto Salvia · 1 shared paper, 2026 · strength 0.26
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.